DIA will host Dried Blood Spot Sampling in the Pharmaceutical Industry: Three Years Of Experience and Implementation from May 3-4, 2011 in Philadelphia, PA. Session topics include:
• Strategic Implementation of DBS Technology
• Hematocrit Eff ects and Impact
• Impact of Sampling Site Location
• Dried Matrix Spots and Alternative Micro-sampling Approaches
• Moving Beyond Small Molecule Quantitation and Pharmacokinetics
Special breakout sessions will explore best practices, advantages and hurdles to implementation and impact of study results.
“Sampling from dried blood spots (DBS) on specialty papers is a novel methodology in the area of pharmacokinetics and toxicokinetics that continues to be an active area of increasing interest and implementation,” says Program Chair Christopher A. Evans, PhD, Section Manager, PTS – DMPK GlaxoSmithKline. “This workshop will focus on the three areas primarily impacted by DBS implementation: bioanalytical, preclinical studies and safety assessment, and clinical studies and clinical pharmacokinetics.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. www.diahome.org